All In Biotech

Drug Trial Radar · NCT03839875

Evaluation of Efficacy and Safety of Gynomax® XL Ovule

A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections

Last checked: Nov 20, 2026Latest source record: Jan 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

116

Actual

Start

Apr 3, 2019

Primary completion

Aug 9, 2019

Study completion Aug 9, 2019

Sponsor

Lead sponsor
Exeltis TurkeyIndustry
Sponsor type
Industry
Collaborators
Monitor CRO
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of Gynomax® XL ovule in the treatment of trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections will be evaluated in this open label, single-arm, multicentral study.

Conditions

  • Trichomonal Vaginitis
  • Bacterial Vaginosis
  • Candidal Vulvovaginitis
  • Mixed Vaginal Infections

Interventions

  • Gynomax® XL Vaginal OvuleDrug

    tioconazole, tinidazole, lidocaine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with complete response to treatmentTime frame: 10 Days after completion of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ege University Family Planning and Infertility Application and Research Centeraştırma Merkezi

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.